ESG Global Impact Capital(DE:L1D)
€0.05+0.00 (+6.12%)
DE:L1D
ESG Global Impact Capital stock drug pipeline
€0.05
At close:+0.00 (+6.12%)
ESG Global Impact Capital (L1D) Drug Pipeline
0 Followers
This company reports no clinical trials.
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Esg Global Impact Capital Inc. (DE:L1D) have in its pipeline
ESG Global Impact Capital DE:L1D does not currently report any drugs in clinical development.

